Paradigm Biopharmaceuticals Limited (PBIGF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Paradigm Biopharmaceuticals Limited (PBIGF) trades at $0.15 with AI Score 41/100 (Grade C). Paradigm Biopharmaceuticals Limited is an Australian drug repurposing company focused on developing injectable pentosan polysulfate sodium drugs. Market cap: $65.01M, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for PBIGF: PBIGF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PBIGF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
PBIGF: the 1 perspectives are evenly split.
How is this calculated? →Paradigm Biopharmaceuticals Limited (PBIGF) Healthcare & Pipeline Overview
Paradigm Biopharmaceuticals Limited is an Australian drug repurposing company specializing in pentosan polysulfate sodium drugs for osteoarthritis and other inflammatory conditions. With a focus on injectable treatments, the company operates in the competitive biotechnology sector, marked by ongoing research and development efforts.
What Is the Investment Thesis for PBIGF?
Paradigm Biopharmaceuticals Limited presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on repurposing pentosan polysulfate sodium (PPS) offers a potentially faster and less expensive route to market compared to novel drug development. A key value driver is the successful completion of clinical trials for its lead osteoarthritis treatment, which could unlock significant market potential. The company's negative profit margin of -59585.7% and gross margin of -161.1% highlight the pre-revenue nature of the business and its reliance on future clinical and commercial success. Upcoming clinical trial results represent major catalysts. However, potential risks include clinical trial failures, regulatory hurdles, and the need for additional funding, especially given the current market capitalization of $65.01M.
Based on FMP financials and quantitative analysis
PBIGF Key Highlights
- Market capitalization of $65.01M reflects the company's current valuation and growth potential.
- Negative P/E ratio of -2.87 indicates the company is currently unprofitable, typical for biotechnology firms in the development stage.
- Profit margin of -59585.7% highlights the significant expenses associated with research and development in the biotechnology industry.
- Gross margin of -161.1% reflects the current lack of revenue generation from commercialized products.
- Beta of 0.18 suggests the stock is less volatile than the overall market.
Who Are PBIGF's Competitors?
PBIGF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AURX Nuo Therapeutics, Inc. | $0.96 | -4.95% | $46.47M | 61 |
| IUGNF Imugene Limited | $0.06 | -25.00% | $24.95M | 41 |
| KNTPF Kintor Pharmaceutical Limited | $0.25 | +0.00% | $115.49M | 56 |
| MSCLF Satellos Bioscience Inc. | $6.25 | +11.81% | $96.62M | 52 |
| ORXOF Orexo AB (publ) | $2.90 | +38.10% | $101.87M | 50 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PBIGF's Key Strengths?
- Repurposing strategy reduces development time and cost.
- Focus on injectable PPS drugs for targeted delivery.
- Potential for expansion into multiple therapeutic areas.
- Relatively low beta suggests lower volatility.
What Are PBIGF's Weaknesses?
- Currently unprofitable with negative profit and gross margins.
- Reliance on successful clinical trial outcomes.
- Limited geographic presence.
- Small market capitalization increases vulnerability.
What Could Drive PBIGF Stock Higher?
- Results from ongoing clinical trials for osteoarthritis treatment.
- Potential strategic partnerships with larger pharmaceutical companies.
- Expansion into new therapeutic areas beyond osteoarthritis.
- Pursuit of regulatory approvals in new geographic markets.
- Development of improved drug delivery methods.
What Are the Key Risks for PBIGF?
- Financial-distress signal — its Altman Z-Score of -21.34 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures could negatively impact the company's valuation.
- Regulatory hurdles and delays could delay product commercialization.
- Competition from established pharmaceutical companies.
- Need for additional funding and potential dilution.
- Limited liquidity and price volatility due to OTC market listing.
What Are the Growth Opportunities for PBIGF?
- Expansion into New Therapeutic Areas: Paradigm has the opportunity to expand the application of its pentosan polysulfate sodium (PPS) drug into other therapeutic areas beyond osteoarthritis. This includes exploring its potential in treating mucopolysaccharidosis, Ross River virus, Chikungunya virus, and acute respiratory distress syndrome (ARDS). Success in these areas could significantly broaden the company's market reach. The timeline for this expansion depends on the progress of ongoing and future clinical trials, with potential revenue generation within the next 3-5 years.
- Geographic Expansion: Currently focused on the Australian market, Paradigm has the potential to expand its operations into other geographic regions, such as North America and Europe. These markets represent significant opportunities for growth, particularly given the large patient populations affected by osteoarthritis. The timeline for geographic expansion will depend on regulatory approvals and strategic partnerships, with potential market entry within the next 2-4 years.
- Strategic Partnerships and Licensing Agreements: Paradigm can pursue strategic partnerships and licensing agreements with larger pharmaceutical companies to accelerate the development and commercialization of its PPS drug. These partnerships can provide access to additional funding, expertise, and distribution channels. The timeline for securing such partnerships is uncertain but could be realized within the next 1-2 years, leading to increased revenue and market penetration.
- Advancements in Drug Delivery Methods: Paradigm can explore advancements in drug delivery methods to improve the efficacy and patient experience of its PPS drug. This includes investigating alternative routes of administration, such as oral or topical formulations. Successful development of improved delivery methods could enhance the drug's competitive advantage and market adoption. Research and development in this area could yield results within the next 3-5 years.
- Repurposing for Veterinary Applications: Paradigm can leverage its expertise in PPS to explore opportunities in the veterinary market. Osteoarthritis is a common condition in animals, particularly dogs and horses, creating a potential market for Paradigm's drug. This diversification could provide a new revenue stream and reduce the company's reliance on the human pharmaceutical market. Entry into the veterinary market could be achieved within the next 2-3 years, pending regulatory approvals and market research.
What Opportunities Does PBIGF Have?
- Strategic partnerships with larger pharmaceutical companies.
- Expansion into new geographic markets.
- Development of improved drug delivery methods.
- Repurposing for veterinary applications.
What Threats Does PBIGF Face?
- Clinical trial failures.
- Regulatory hurdles and delays.
- Competition from established pharmaceutical companies.
- Need for additional funding and potential dilution.
What Are PBIGF's Competitive Advantages?
- Proprietary formulations of pentosan polysulfate sodium (PPS).
- Intellectual property protection through patents.
- Clinical data supporting the efficacy and safety of its drugs.
- Repurposing strategy potentially reduces development time and cost.
What Does PBIGF Do?
Paradigm Biopharmaceuticals Limited, incorporated in 2014 and based in Melbourne, Australia, is a drug repurposing company dedicated to the research and development of therapeutic products for human use. The company's core focus lies in developing and commercializing pentosan polysulfate sodium (PPS) drugs in injectable form. These drugs are being investigated for the treatment of various conditions, including osteoarthritis, mucopolysaccharidosis, Ross River virus, Chikungunya virus, and acute respiratory distress syndrome (ARDS). Paradigm's strategy centers around identifying existing drugs with potential for new therapeutic applications. By repurposing these drugs, the company aims to reduce the time and cost associated with traditional drug development pathways. The company's lead product candidate is focused on addressing the unmet needs in osteoarthritis treatment. Paradigm is actively engaged in clinical trials to evaluate the safety and efficacy of its PPS drug in specific indications. The company operates primarily within Australia, with potential for future expansion into other geographic markets as its pipeline progresses.
What Products and Services Does PBIGF Offer?
- Develops injectable pentosan polysulfate sodium (PPS) drugs.
- Focuses on repurposing existing drugs for new therapeutic applications.
- Conducts clinical trials to evaluate the safety and efficacy of its drugs.
- Targets the treatment of osteoarthritis and other inflammatory conditions.
- Operates primarily in the Australian pharmaceutical market.
- Aims to commercialize its PPS drug for various indications.
How Does PBIGF Make Money?
- Develop and patent repurposed drugs.
- Conduct clinical trials to demonstrate efficacy and safety.
- Seek regulatory approval for commercialization.
- Potentially partner with larger pharmaceutical companies for distribution and marketing.
What Industry Does PBIGF Operate In?
Paradigm Biopharmaceuticals operates within the biotechnology industry, a sector characterized by high innovation, long development cycles, and significant regulatory oversight. The market for osteoarthritis treatments is substantial and growing, driven by an aging population and increasing rates of obesity. Paradigm's competitors include companies such as Aurinia Pharmaceuticals (AURX), focused on autoimmune diseases, and other firms developing therapies for inflammatory conditions. The biotechnology industry is subject to intense competition, rapid technological advancements, and evolving regulatory landscapes.
Who Are PBIGF's Key Customers?
- Patients suffering from osteoarthritis.
- Healthcare providers prescribing treatments for osteoarthritis.
- Potential pharmaceutical partners seeking to license or acquire Paradigm's drugs.
How Paradigm Biopharmaceuticals Limited Is Valued
Paradigm Biopharmaceuticals Limited carries a market capitalization of $65.01M, placing it in the micro-cap category. Relative to its peer group, PBIGF's quantitative score of 41/100 is below the peer average of 52/100.
Key Financial Metrics
Its free cash flow yield is -10.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.31 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -48.5%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 2/9Financial Health
Paradigm Biopharmaceuticals Limited's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -21.34 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project Paradigm Biopharmaceuticals Limited revenue of about $3.0M for fiscal 2026, with EPS near $-0.09.
PBIGF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Paradigm's pipeline and potential breakthroughs.
- Community sentiment has shifted positively, with discussions around upcoming clinical trial results gaining traction.
- Investors are optimistic about the company's focus on innovative therapies for osteoarthritis, which addresses a significant market need.
- Positive media coverage highlighting Paradigm's advancements has bolstered public perception and interest.
Bear Case
- Concerns linger over the timeline for regulatory approvals, which could delay potential revenue streams.
- Community discussions reflect skepticism regarding the scalability of Paradigm's treatments in a competitive landscape.
- Recent bearish sentiment indicates worries about funding and cash flow, especially in the biotech sector's volatility.
- Insider selling activity has raised red flags for some investors, suggesting uncertainty about future performance.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
PBIGF Latest News
No recent news available for PBIGF.
PBIGF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PBIGF.
Price Targets
Wall Street price target analysis for PBIGF.
PBIGF MoonshotScore
What does this score mean?
The MoonshotScore rates PBIGF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Paul John Rennie
CEO
Paul John Rennie serves as the Chief Executive Officer of Paradigm Biopharmaceuticals Limited. His background includes extensive experience in the pharmaceutical and biotechnology industries, with a focus on drug development and commercialization. He has held leadership positions in various companies, contributing to the advancement of innovative therapies. His expertise spans clinical research, regulatory affairs, and business development, providing a comprehensive understanding of the pharmaceutical landscape. He is responsible for guiding Paradigm's strategic direction and overseeing its operational activities.
Track Record: Under Paul John Rennie's leadership, Paradigm Biopharmaceuticals has focused on advancing its clinical pipeline, particularly the development of its pentosan polysulfate sodium (PPS) drug for osteoarthritis. Key milestones include initiating and progressing clinical trials, securing regulatory approvals, and fostering strategic partnerships. His leadership has been instrumental in driving the company's growth and establishing its position in the biotechnology sector.
PBIGF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Paradigm Biopharmaceuticals Limited (PBIGF) may not meet the minimum financial or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited operating history, may be thinly traded, and are subject to less stringent regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries a higher degree of risk due to the potential for fraud, lack of liquidity, and limited information availability.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited liquidity and potential for price volatility.
- Less stringent regulatory oversight compared to major exchanges.
- Potential for limited or inconsistent financial disclosures.
- Higher risk of fraud or manipulation.
- Greater difficulty in obtaining reliable information about the company.
- Verify the company's registration and regulatory filings.
- Review available financial statements and disclosures.
- Assess the company's management team and track record.
- Research the company's business model and competitive landscape.
- Evaluate the company's capital structure and funding sources.
- Monitor trading volume and price activity.
- Consult with a qualified financial advisor.
- Established business operations in Australia.
- Focus on drug development and clinical trials.
- Intellectual property protection through patents.
- Presence of a CEO with experience in the pharmaceutical industry.
- Publicly traded status, even on the OTC market, suggests some level of regulatory scrutiny.
Common Questions About PBIGF (Healthcare)
What does Paradigm Biopharmaceuticals Limited do?
Paradigm Biopharmaceuticals Limited is a drug repurposing company focused on developing injectable pentosan polysulfate sodium (PPS) drugs for the treatment of osteoarthritis and other inflammatory conditions. The company's business model involves identifying existing drugs with potential for new therapeutic applications, conducting clinical trials to demonstrate efficacy and safety, and seeking regulatory approval for commercialization. Paradigm's lead product candidate is focused on addressing the unmet needs in osteoarthritis treatment, with potential expansion into other therapeutic areas such as mucopolysaccharidosis and acute respiratory distress syndrome (ARDS).
What are the main risks for PBIGF?
The main risks for Paradigm Biopharmaceuticals Limited include clinical trial failures, which could significantly impact the company's valuation and future prospects. Regulatory hurdles and delays in obtaining approvals for its drugs pose another risk. Competition from established pharmaceutical companies with greater resources and market presence is also a concern. The company's need for additional funding and potential dilution of existing shareholders represents a financial risk. Additionally, the limited liquidity and price volatility associated with trading on the OTC market add to the overall risk profile.
What are the key factors to evaluate for PBIGF?
Paradigm Biopharmaceuticals Limited (PBIGF) holds an AI score of 41/100 (low). Not financial advice.
How frequently does PBIGF data refresh on this page?
PBIGF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven PBIGF's recent stock price performance?
Paradigm Biopharmaceuticals Limited (PBIGF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Repurposing strategy reduces development time and cost. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PBIGF overvalued or undervalued right now?
Valuing Paradigm Biopharmaceuticals Limited (PBIGF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying PBIGF?
Before investing in Paradigm Biopharmaceuticals Limited (PBIGF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding PBIGF to a portfolio?
Key strength of Paradigm Biopharmaceuticals Limited (PBIGF): Repurposing strategy reduces development time and cost. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be limited or inconsistent.
- AI analysis is pending for PBIGF.